TNSN96163A1 - Formulations injectables de quinolones - Google Patents

Formulations injectables de quinolones

Info

Publication number
TNSN96163A1
TNSN96163A1 TNTNSN96163A TNSN96163A TNSN96163A1 TN SN96163 A1 TNSN96163 A1 TN SN96163A1 TN TNSN96163 A TNTNSN96163 A TN TNSN96163A TN SN96163 A TNSN96163 A TN SN96163A TN SN96163 A1 TNSN96163 A1 TN SN96163A1
Authority
TN
Tunisia
Prior art keywords
quinolones
injectable formulations
injection
danofloxacin
magnesium
Prior art date
Application number
TNTNSN96163A
Other languages
English (en)
Inventor
Alan Boettner Wayne
Connor Canning Pter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN96163(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN96163A1 publication Critical patent/TNSN96163A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

L'INVENTION CONCERNE DES SOLUTIONS PHARMACEUTIQUES ACQUEUSES APTES A L'INJECTION. CES SOLUTIONS COMPRENNENT DE LA DANOFLOXACINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN COMPOSE DE MAGNESIUM OU DE ZINC EN PRESENCE D'UN CO-SOLVANT. APPLICATION : TRAITEMENT D'INFECTIONS BACTERIENNES PAR INJECTION SOUS-CUTANEE, AVEC UNE TOLERANCE AMELIOREE AU SITE D'INJECTION.
TNTNSN96163A 1995-12-21 1996-12-18 Formulations injectables de quinolones TNSN96163A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
TNSN96163A1 true TNSN96163A1 (fr) 2005-03-15

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96163A TNSN96163A1 (fr) 1995-12-21 1996-12-18 Formulations injectables de quinolones

Country Status (42)

Country Link
US (1) US5811130A (fr)
EP (1) EP0868183B1 (fr)
JP (1) JP3416145B2 (fr)
KR (1) KR100402570B1 (fr)
CN (1) CN1104899C (fr)
AP (1) AP706A (fr)
AR (1) AR005147A1 (fr)
AT (1) ATE212551T1 (fr)
AU (1) AU709474B2 (fr)
BG (1) BG63933B1 (fr)
BR (1) BR9612230A (fr)
CA (1) CA2239352C (fr)
CO (1) CO4480098A1 (fr)
CZ (1) CZ293747B6 (fr)
DE (1) DE69618987T2 (fr)
DK (1) DK0868183T3 (fr)
DZ (1) DZ2146A1 (fr)
EG (1) EG24071A (fr)
ES (1) ES2167609T3 (fr)
GT (1) GT199600098A (fr)
HR (1) HRP960607B1 (fr)
HU (1) HU227918B1 (fr)
IL (1) IL124454A (fr)
IS (1) IS2010B (fr)
MA (1) MA24035A1 (fr)
MX (1) MX9805026A (fr)
MY (1) MY117109A (fr)
NO (1) NO315734B1 (fr)
NZ (2) NZ501160A (fr)
OA (1) OA10697A (fr)
PE (1) PE25798A1 (fr)
PL (1) PL186795B1 (fr)
PT (1) PT868183E (fr)
RS (1) RS49523B (fr)
RU (1) RU2141827C1 (fr)
SI (1) SI0868183T1 (fr)
SK (1) SK284412B6 (fr)
TN (1) TNSN96163A1 (fr)
TW (1) TW449475B (fr)
UA (1) UA56151C2 (fr)
WO (1) WO1997023217A1 (fr)
ZA (1) ZA9610780B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
EP1255565A1 (fr) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Compositions pharmaceutiques contenant de la 2-pyrrolidone en tant qu'agent de solubilisation
EP1356809A4 (fr) * 2000-12-28 2008-05-14 Takeda Pharmaceutical Preparations a liberation soutenue
EP1524997A1 (fr) * 2002-06-26 2005-04-27 Pharmacia Corporation Formulation de parecoxib liquide stable administree par voie parenterale
CA2572167A1 (fr) * 2004-07-02 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Composition medicinale contenant de la quinolone
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
MX2008010222A (es) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (fr) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation de levofloxacine pour reduire une inflammation des poumons
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2987879A1 (fr) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Medicament aqueux
WO2016195020A1 (fr) 2015-06-02 2016-12-08 杏林製薬株式会社 Médicament aqueux
CA2988092A1 (fr) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Formulation liquide aqueuse
WO2018146194A1 (fr) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Composition liquide contenant de la pradofloxacine
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
CA2072366C (fr) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Complexes d'acide carboxylique d'une quinolone-ion d'un metal-acide
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
DE69102900T3 (de) * 1990-02-14 1998-04-09 Takeda Chemical Industries Ltd Brausemischung, deren Herstellung sowie Verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HUP9903726A3 (en) 2001-01-29
KR19990076617A (ko) 1999-10-15
ES2167609T3 (es) 2002-05-16
IS2010B (is) 2005-05-13
PE25798A1 (es) 1998-05-21
JP3416145B2 (ja) 2003-06-16
DZ2146A1 (fr) 2002-10-23
HU227918B1 (en) 2012-06-28
CO4480098A1 (es) 1997-07-09
DE69618987T2 (de) 2002-11-21
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
NO315734B1 (no) 2003-10-20
SK284412B6 (sk) 2005-03-04
NO982842L (no) 1998-06-19
MX9805026A (es) 1998-09-30
CZ193098A3 (cs) 1999-05-12
JPH11501331A (ja) 1999-02-02
BG102542A (en) 1999-06-30
NZ320545A (en) 2000-03-27
KR100402570B1 (ko) 2003-12-18
ATE212551T1 (de) 2002-02-15
PL328001A1 (en) 1999-01-04
TW449475B (en) 2001-08-11
CZ293747B6 (cs) 2004-07-14
BG63933B1 (bg) 2003-07-31
EG24071A (en) 2008-05-11
CA2239352A1 (fr) 1997-07-03
IL124454A0 (en) 1998-12-06
CN1104899C (zh) 2003-04-09
HUP9903726A2 (hu) 2000-04-28
OA10697A (en) 2001-05-04
IL124454A (en) 2003-10-31
CA2239352C (fr) 2002-06-04
HRP960607B1 (en) 2002-06-30
YU69096A (sh) 1999-06-15
DE69618987D1 (de) 2002-03-14
UA56151C2 (uk) 2003-05-15
SK80798A3 (en) 1999-09-10
BR9612230A (pt) 1999-07-13
EP0868183A1 (fr) 1998-10-07
RS49523B (sr) 2006-10-27
US5811130A (en) 1998-09-22
HRP960607A2 (en) 1998-06-30
WO1997023217A1 (fr) 1997-07-03
NZ501160A (en) 2001-10-26
SI0868183T1 (en) 2002-04-30
MY117109A (en) 2004-05-31
NO982842D0 (no) 1998-06-19
AU7328996A (en) 1997-07-17
GT199600098A (es) 1998-06-12
IS4755A (is) 1998-05-25
DK0868183T3 (da) 2002-03-25
ZA9610780B (en) 1998-06-22
PL186795B1 (pl) 2004-02-27
AR005147A1 (es) 1999-04-14
CN1205636A (zh) 1999-01-20
RU2141827C1 (ru) 1999-11-27
AP9600898A0 (en) 1997-01-31
PT868183E (pt) 2002-06-28
EP0868183B1 (fr) 2002-01-30
MA24035A1 (fr) 1997-07-01

Similar Documents

Publication Publication Date Title
TNSN96163A1 (fr) Formulations injectables de quinolones
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
UA40663C2 (uk) Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BG105600A (en) 13-membered azalides and their use as antibiotic agents
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
Gerber et al. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
TNSN97042A1 (fr) Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant.